55857-63-1

Upstream product

• 64-17-5 ethanol 
• 67123-97-1 (R,S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 

Downstream Products

• 91544-03-5 3-acetylisoquinoline 
• 1254944-66-5 ethyl 2-(5-(methylthio)thiophene-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 1380547-82-9 3-ethyl 2-(3-(trifluoromethyl)phenyl) 3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate 
• 1262842-13-6 C₁₉H₂₁NO₄S 
• 1380547-84-1 3-ethyl 2-phenyl 3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate 
• 101195-64-6 ethyl 2-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 1380547-77-2 C₁₉H₁₈ClNO₃ 
• 1380547-80-7 C₁₈H₁₈BrNO₄S 
• 1380548-02-6 C₃₁H₃₁NO₃ 
• 1380547-98-7 (3-(([1,1'-biphenyl]-4-yloxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone 
• 1380547-97-6 C₂₇H₂₂FNO₂ 
• 1380547-96-5 C₂₈H₂₆N₂O 
• 1380547-95-4 C₂₉H₂₆N₂O₃ 
• 1380547-94-3 C₂₇H₂₄N₂O₃S 

Relevant academic research and scientific papers

Evaluation of animal liver acetone powders for the resolution of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

Butyl, ethyl and methyl esters of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid were hydrolyzed stereoselectively under very mild conditions to give the corresponding (S)-acid and the unreacted (R)-ester using readily available animal liver (chicken, mouse, rat and rabbit) acetone powders.

NATURAL KILLER CELLS

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.

MODULATORS OF REV-ERB

The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, a bone-related disorder such osteoporosis, a skeletal muscle disease, e.g., with compromised exercise capacity, or an autoimmune disorder such as psoriasis, multiple sclerosis, inflammatory bowel disease, and others.

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID AND CYCLIC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS

This invention is directed to benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.